Liora Life Sciences, LLC — SEC Form D Filing

Liora Life Sciences, LLC filed an SEC Form D on October 1, 2026, reporting $300K raised in Other Health Care.

Form D filing details

Filing
SEC Form D
Filing date
October 1, 2026
Amount reported
$300K
Round stage
Pre-seed because the $300,000 raise is characteristic of early-stage capital used to fund initial laboratory validation and proof-of-concept studies.
Industry
Other Health Care
Website
https://lioralifesciences.com

What the company does

Securities: Equity. Exemption: Rule 506(c). Incorporated: DELAWARE

Problem

Early-stage drug discovery and therapeutic development suffer from high attrition rates and prolonged timelines due to inefficient preclinical screening models.

Solution

Liora Life Sciences develops advanced biological assays and therapeutic platforms to streamline the identification of viable drug candidates.

Why now

The convergence of high-throughput screening technologies and machine learning has created unprecedented opportunities to optimize early-stage therapeutic pipelines.

Source: SEC EDGAR Form D filing